The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Pulmonary Hypertension due to Lung Diseases (Group 3)

Pulmonary hypertension secondary to chronic obstructive, interstitial, or other parenchymal lung disease, requiring careful evaluation and a focus on optimizing underlying disease before targeted PAH therapy.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Göğüs Hastalıkları department. Book Appointment →

What is Pulmonary Hypertension due to Lung Diseases (Group 3)?

Group 3 PH pathophysiology: chronic alveolar hypoxia (most important), inflammatory mediators, parenchymal destruction (vascular bed loss), endothelial dysfunction, and hypoxic pulmonary vasoconstriction. Sympathetic activation, neurohormonal alteration, and right ventricular adaptation/maladaptation determine clinical course.

Common etiologies: COPD (5-50% develop PH; severe PH in <5%), IPF and other ILDs (30-85% develop PH at end-stage), CPFE (severe PH in 30-50%, prognosis worse than COPD or IPF alone), bronchiectasis, cystic fibrosis, sarcoidosis stage IV, sleep-disordered breathing.

Diagnosis requires right heart catheterization (RHC) with mPAP ≥25 mmHg (≥20 mmHg in newer criteria), pulmonary capillary wedge pressure ≤15 mmHg, and exclusion of left heart disease. Echocardiography is screening tool; RHC confirms and quantifies severity.

Symptoms

Disproportionate dyspnea on exertion compared to lung disease severity
Fatigue, reduced exercise tolerance
Syncope or near-syncope on exertion (severe PH)
Chest pain (right heart strain)
Lower extremity edema (right heart failure)
Hypoxemia at rest or exertion (often severe)
Cyanosis (severe disease)
Symptoms of underlying lung disease (cough, sputum, wheezing)

Risk Factors

Chronic obstructive pulmonary disease (severe, GOLD III-IV)
Idiopathic pulmonary fibrosis or other ILDs
Combined pulmonary fibrosis and emphysema (CPFE)
Connective tissue disease (scleroderma, RA, MCTD with ILD)
Severe chronic hypoxia (resting SpO2 <88%, sleep desaturation)
Obstructive sleep apnea, obesity hypoventilation syndrome
High-altitude residence (chronic mountain sickness)
Smoking history (COPD, emphysema, fibrosis)

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Disproportionate dyspnea relative to lung disease severity
  • Severe hypoxemia, exertional desaturation
  • Right heart failure signs in lung disease patient
  • Echocardiographic estimated PASP >40-50 mmHg in lung disease
  • Pulmonology and PH specialty center referral for evaluation

Treatment Methods

01
Diagnostic workup: echocardiography (TR jet velocity, PASP estimate, RV function), pulmonary function tests (severity of underlying disease), HRCT (parenchymal characterization, exclude CTEPH), 6-minute walk test, BNP/NT-proBNP, polysomnography for sleep apnea, ABG and exercise oximetry
02
Right heart catheterization indication: when severe PH suspected (echo PASP >50 mmHg or RV dysfunction), when treatment decisions hinge on exact hemodynamics, lung transplant evaluation; differentiates Group 3 from Group 2 (left heart) and CTEPH
03
Optimize underlying lung disease: maximal COPD therapy (LABA/LAMA, ICS if asthmatic features, pulmonary rehabilitation, smoking cessation); IPF antifibrotics (pirfenidone, nintedanib); ILD specific therapy
04
Long-term oxygen therapy (LTOT): SpO2 ≥90% or PaO2 ≥60 mmHg target; eligibility resting PaO2 <55 mmHg or 55-59 with cor pulmonale or polycythemia; nocturnal/exertional supplementation as needed; LTOT reduces PH progression and mortality
05
Treatment of contributing factors: sleep apnea (CPAP), obesity hypoventilation (BiPAP/AVAPS), pulmonary rehabilitation
06
PAH-targeted therapy in Group 3 — controversial: most studies show no benefit or worsening V/Q matching with vasodilators (sildenafil, ambrisentan, riociguat) in COPD or unselected ILDs; bosentan harmful in IPF
07
INCREASE trial (2021): inhaled treprostinil improved 6MWT distance and reduced clinical worsening in ILD-associated PH (FDA-approved 2021); first targeted therapy with positive data in Group 3
08
Selective use of oral PAH therapy in severe Group 3 PH: consider only at expert PH centers with phenotype of severe PH despite optimal lung disease management; sildenafil for selected COPD with severe PH
09
Right heart failure management: diuretics, salt restriction, monitor electrolytes; avoid excessive fluid restriction (preload-dependent)
10
Lung transplantation: end-stage with PH; PH worsens prognosis on waiting list; evaluation referral when severely limited
11
Pulmonary rehabilitation: improves exercise capacity, dyspnea, quality of life across Group 3 phenotypes
12
Multidisciplinary care: pulmonology with ILD/PH expertise, cardiology, sleep medicine, transplant team
13
Prognosis: severe PH in lung disease portends poor prognosis (median survival 1-3 years in IPF-PH); Group 3 PH overall worse than idiopathic PAH; depends on underlying disease severity and PH severity

Which Department to Visit?

You can visit our Göğüs Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Göğüs Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Asthma

Göğüs Hastalıkları

Asthma is characterized by wheezing, coughing and shortness of breath attacks; with proper treatment it can be kept under control.

COPD (Chronic Obstructive Pulmonary Disease)

Göğüs Hastalıkları

COPD is an irreversible lung disease characterized by shortness of breath and chronic cough; quitting smoking slows its progression.

Pneumonia

Göğüs Hastalıkları

Pneumonia presents with high fever, cough and shortness of breath; the vast majority recover with appropriate antibiotic treatment.

Tuberculosis (TB)

Göğüs Hastalıkları

Tuberculosis presents with weeks-to-months of cough, fever, and night sweats; early diagnosis and treatment lead to full recovery.

Pleural Effusion

Göğüs Hastalıkları

Pleural effusion is the accumulation of excess fluid in the pleural space, resulting from imbalances in fluid production and removal, and represents a manifestation of diverse cardiopulmonary, infectious, and malignant disorders.

Pneumothorax

Göğüs Hastalıkları

Pneumothorax is the presence of air in the pleural space resulting in partial or complete lung collapse, classified as spontaneous (primary/secondary), traumatic, or iatrogenic, with tension pneumothorax representing a life-threatening emergency.

Bronchitis (Acute and Chronic)

Göğüs Hastalıkları

Acute bronchitis is mostly viral and resolves spontaneously, while chronic bronchitis is a smoking-related component of COPD.

Bronchiectasis

Göğüs Hastalıkları

Bronchiectasis is a chronic respiratory disease characterized by permanent, abnormal dilation of bronchi with associated destruction of muscular and elastic components of airway walls, resulting in impaired mucociliary clearance and recurrent infection.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.